RO7795081
Sponsors
F. Hoffmann-La Roche AG, Hoffmann-La Roche
Conditions
Healthy ParticipantsHealthy VolunteersObesityObesity or OverweightOverweightOverweight or ObesityRenal ImpairmentType 2 Diabetes Mellitus
Phase 1
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
CompletedNCT06809608
Start: 2025-02-13End: 2025-06-16Updated: 2025-07-08
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
Active, not recruitingNCT06982131
Start: 2025-06-04End: 2026-12-07Target: 40Updated: 2026-09-09
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Active, not recruitingNCT07499050
Start: 2026-03-30End: 2027-01-09Target: 30Updated: 2026-08-10
A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions
RecruitingNCT07741604
Start: 2026-09-09End: 2028-02-01Target: 60Updated: 2026-09-11
Phase 2
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
CompletedNCT07081958
Start: 2025-07-29End: 2026-07-30Updated: 2026-08-21
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Active, not recruitingNCT07112872
Start: 2025-08-19End: 2026-11-27Target: 240Updated: 2026-07-07
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus
RecruitingCTIS2024-520322-11-00
Start: 2025-09-29Target: 74Updated: 2025-09-08